Open Access
Open access
volume 6 issue 1 pages e16145

Stepwise Release of Biologically Active HMGB1 during HSV-2 Infection

Chloé Borde 1
Stéphanie Barnay-Verdier 1
Claire Gaillard 1
Hakim Hocini 2
Vincent Maréchal 1
Joël Gozlan 3
Publication typeJournal Article
Publication date2011-01-19
scimago Q1
wos Q2
SJR0.803
CiteScore5.4
Impact factor2.6
ISSN19326203
Multidisciplinary
Abstract
Background High mobility group box 1 protein (HMGB1) is a major endogenous danger signal that triggers inflammation and immunity during septic and aseptic stresses. HMGB1 recently emerged as a key soluble factor in the pathogenesis of various infectious diseases, but nothing is known of its behaviour during herpesvirus infection. We therefore investigated the dynamics and biological effects of HMGB1 during HSV-2 infection of epithelial HEC-1 cells. Methodology/Principal Findings Despite a transcriptional shutdown of HMGB1 gene expression during infection, the intracellular pool of HMGB1 protein remained unaffected, indicating its remarkable stability. However, the dynamics of HMGB1 was deeply modified in infected cells. Whereas viral multiplication was concomitant with apoptosis and HMGB1 retention on chromatin, a subsequent release of HMGB1 was observed in response to HSV-2 mediated necrosis. Importantly, extracellular HMGB1 was biologically active. Indeed, HMGB1-containing supernatants from HSV-2 infected cells induced the migration of fibroblasts from murine or human origin, and reactivated HIV-1 from latently infected T lymphocytes. These effects were specifically linked to HMGB1 since they were blocked by glycyrrhizin or by a neutralizing anti-HMGB1 antibody, and were mediated through TLR2 and the receptor for Advanced Glycation End-products (RAGE). Finally, we show that genital HSV-2 active infections also promote HMGB1 release in vivo, strengthening the clinical relevance of our experimental data. Conclusions These observations target HMGB1 as an important actor during HSV-2 genital infection, notably in the setting of HSV-HIV co-infection.
Found 
Found 

Top-30

Journals

1
2
3
4
5
Journal of Virology
5 publications, 13.16%
Viruses
4 publications, 10.53%
PLoS ONE
2 publications, 5.26%
Journal of Immunology
1 publication, 2.63%
Oncotarget
1 publication, 2.63%
AIDS Research and Human Retroviruses
1 publication, 2.63%
Journal of General Virology
1 publication, 2.63%
Biomedicines
1 publication, 2.63%
Medicines
1 publication, 2.63%
Microorganisms
1 publication, 2.63%
Pathogens
1 publication, 2.63%
Frontiers in Oncology
1 publication, 2.63%
Scientific Reports
1 publication, 2.63%
Cancer Gene Therapy
1 publication, 2.63%
Cell Death and Differentiation
1 publication, 2.63%
Molecular Cancer
1 publication, 2.63%
Calcified Tissue International
1 publication, 2.63%
PLoS Neglected Tropical Diseases
1 publication, 2.63%
Immunobiology
1 publication, 2.63%
Journal of Clinical Virology
1 publication, 2.63%
Cellular Immunology
1 publication, 2.63%
Pharmacology and Therapeutics
1 publication, 2.63%
Cytokine and Growth Factor Reviews
1 publication, 2.63%
Reviews in Medical Virology
1 publication, 2.63%
European Journal of Neuroscience
1 publication, 2.63%
Advances in Experimental Medicine and Biology
1 publication, 2.63%
Virulence
1 publication, 2.63%
Clinical Cancer Research
1 publication, 2.63%
Asian Pacific Journal of Tropical Medicine
1 publication, 2.63%
Microbiology spectrum
1 publication, 2.63%
1
2
3
4
5

Publishers

1
2
3
4
5
6
7
8
MDPI
8 publications, 21.05%
Springer Nature
6 publications, 15.79%
American Society for Microbiology
6 publications, 15.79%
Elsevier
5 publications, 13.16%
Public Library of Science (PLoS)
3 publications, 7.89%
Wiley
2 publications, 5.26%
The American Association of Immunologists
1 publication, 2.63%
Impact Journals
1 publication, 2.63%
Mary Ann Liebert
1 publication, 2.63%
Microbiology Society
1 publication, 2.63%
Frontiers Media S.A.
1 publication, 2.63%
Taylor & Francis
1 publication, 2.63%
American Association for Cancer Research (AACR)
1 publication, 2.63%
Ovid Technologies (Wolters Kluwer Health)
1 publication, 2.63%
1
2
3
4
5
6
7
8
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
38
Share
Cite this
GOST |
Cite this
GOST Copy
Borde C. et al. Stepwise Release of Biologically Active HMGB1 during HSV-2 Infection // PLoS ONE. 2011. Vol. 6. No. 1. p. e16145.
GOST all authors (up to 50) Copy
Borde C., Barnay-Verdier S., Gaillard C., Hocini H., Maréchal V., Gozlan J. Stepwise Release of Biologically Active HMGB1 during HSV-2 Infection // PLoS ONE. 2011. Vol. 6. No. 1. p. e16145.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1371/journal.pone.0016145
UR - https://doi.org/10.1371/journal.pone.0016145
TI - Stepwise Release of Biologically Active HMGB1 during HSV-2 Infection
T2 - PLoS ONE
AU - Borde, Chloé
AU - Barnay-Verdier, Stéphanie
AU - Gaillard, Claire
AU - Hocini, Hakim
AU - Maréchal, Vincent
AU - Gozlan, Joël
PY - 2011
DA - 2011/01/19
PB - Public Library of Science (PLoS)
SP - e16145
IS - 1
VL - 6
PMID - 21283827
SN - 1932-6203
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2011_Borde,
author = {Chloé Borde and Stéphanie Barnay-Verdier and Claire Gaillard and Hakim Hocini and Vincent Maréchal and Joël Gozlan},
title = {Stepwise Release of Biologically Active HMGB1 during HSV-2 Infection},
journal = {PLoS ONE},
year = {2011},
volume = {6},
publisher = {Public Library of Science (PLoS)},
month = {jan},
url = {https://doi.org/10.1371/journal.pone.0016145},
number = {1},
pages = {e16145},
doi = {10.1371/journal.pone.0016145}
}
MLA
Cite this
MLA Copy
Borde, Chloé, et al. “Stepwise Release of Biologically Active HMGB1 during HSV-2 Infection.” PLoS ONE, vol. 6, no. 1, Jan. 2011, p. e16145. https://doi.org/10.1371/journal.pone.0016145.